Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 10x Genomics, Inc.TXG · Entity 2172 | Director · See Remarks | August 24, 2026 | August 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
10x Genomics, Inc.
Report date August 24, 2026 · Filed August 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 488,182 |
Reported balance
After 2026-08-24 transaction · row 1
1 source rowRow 1 · 2026-08-24 · Sale · Disposed 13,818 · Balance 488,182 F1: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2: This transaction was executed in multiple trades at prices ranging from $63.0088 to $63.78, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
F2: This transaction was executed in multiple trades at prices ranging from $63.0088 to $63.78, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 22, 2022 Filed Feb 25, 2022 00:40 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 360 | $78.59 | $28,293.98 |
DisclosureSEC source: 0001567619-22-005522 · doc1.xml · nonDerivative · entry 1 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,326 F1 · shares: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 39,582 | $0.00 Strike: $74.58 | $0.00 |
DisclosureSEC source: 0001567619-22-000621 · doc1.xml · derivative · entry 10 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,630 Underlying: Class A Common Stock · 39,582 shares Expires 2030-04-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F9 · derivative.exercise_date: This option, originally for 136,000 shares, of which 42,370 shares have been exercised, vested as to 1/48th of the shares on May 1, 2020 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 2,084 | $0.00 Strike: $11.48 | $0.00 |
DisclosureSEC source: 0001567619-22-000621 · doc1.xml · derivative · entry 9 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,250 Underlying: Class A Common Stock · 2,084 shares Expires 2029-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F8 · derivative.exercise_date: This option, originally for 100,000 shares, of which 68,750 shares have been exercised, vested as to 1/48th of the shares on May 1, 2019 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 600 | $149.24 | $89,545.98 |
DisclosureSEC source: 0001567619-22-000621 · doc1.xml · nonDerivative · entry 8 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,686 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $149.09 to $149.47. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,000 | $148.44 | $296,871.00 |
DisclosureSEC source: 0001567619-22-000621 · doc1.xml · nonDerivative · entry 7 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,286 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $147.93 to $148.925. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,906 | $147.34 | $428,160.16 |
DisclosureSEC source: 0001567619-22-000621 · doc1.xml · nonDerivative · entry 6 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,286 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $146.89 to $147.87. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 17,396 | $146.29 | $2,544,926.94 |
DisclosureSEC source: 0001567619-22-000621 · doc1.xml · nonDerivative · entry 5 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,192 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $145.89 to $146.8725. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 16,464 | $145.43 | $2,394,422.08 |
DisclosureSEC source: 0001567619-22-000621 · doc1.xml · nonDerivative · entry 4 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,588 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $144.89 to $145.88. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,300 | $144.56 | $332,477.88 |
DisclosureSEC source: 0001567619-22-000621 · doc1.xml · nonDerivative · entry 3 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,052 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $143.89 to $144.85. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 39,582 | $74.58 | $2,952,025.56 |
DisclosureSEC source: 0001567619-22-000621 · doc1.xml · nonDerivative · entry 2 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 2,084 | $11.48 | $23,924.32 |
DisclosureSEC source: 0001567619-22-000621 · doc1.xml · nonDerivative · entry 1 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,770 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| December 28, 2021 Filed Dec 31, 2021 00:31 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 59,968 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001567619-21-022724 · doc1.xml · derivative · entry 4 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 59,968 shares Expires 2027-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| December 28, 2021 Filed Dec 31, 2021 00:31 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 53,952 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001567619-21-022724 · doc1.xml · derivative · entry 3 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 53,952 shares Expires 2026-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| December 28, 2021 Filed Dec 31, 2021 00:31 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 59,968 | $1.20 | $71,961.60 |
DisclosureSEC source: 0001567619-21-022724 · doc1.xml · nonDerivative · entry 2 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,686 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2021 Filed Dec 31, 2021 00:31 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 53,952 | $1.07 | $57,728.64 |
DisclosureSEC source: 0001567619-21-022724 · doc1.xml · nonDerivative · entry 1 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 2,788 | $0.00 Strike: $74.58 | $0.00 |
DisclosureSEC source: 0001567619-21-021615 · doc1.xml · derivative · entry 16 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,212 Underlying: Class A Common Stock · 2,788 shares Expires 2030-04-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F12 · derivative.exercise_date: This option, originally for 136,000 shares, of which 2,788 shares have been exercised, vested as to 1/48th of the shares on May 1, 2020 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 35,232 | $0.00 Strike: $11.48 | $0.00 |
DisclosureSEC source: 0001567619-21-021615 · doc1.xml · derivative · entry 15 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,334 Underlying: Class A Common Stock · 35,232 shares Expires 2029-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F11 · derivative.exercise_date: This option, originally for 100,000 shares, of which 66,666 shares have been exercised, vested as to 1/48th of the shares on May 1, 2019 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 3,646 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001567619-21-021615 · doc1.xml · derivative · entry 14 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,238 Underlying: Class A Common Stock · 3,646 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F10 · derivative.exercise_date: This option, originally for 175,000 shares, of which 127,762 shares have been exercised, vested as to 1/48th of the shares on October 1, 2018 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 200 | $155.55 | $31,110.00 |
DisclosureSEC source: 0001567619-21-021615 · doc1.xml · nonDerivative · entry 13 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,766 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 700 | $153.91 | $107,739.52 |
DisclosureSEC source: 0001567619-21-021615 · doc1.xml · nonDerivative · entry 12 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,966 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F9 · price: This transaction was executed in multiple trades at prices ranging from $153.665 to $154.08. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $152.25 | $15,225.00 |
DisclosureSEC source: 0001567619-21-021615 · doc1.xml · nonDerivative · entry 11 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,666 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,100 | $151.46 | $318,060.54 |
DisclosureSEC source: 0001567619-21-021615 · doc1.xml · nonDerivative · entry 10 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,766 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $151.14 to $152.065. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,816 | $150.66 | $273,602.37 |
DisclosureSEC source: 0001567619-21-021615 · doc1.xml · nonDerivative · entry 9 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,866 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $150.12 to $151.11. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,849 | $149.46 | $724,718.45 |
DisclosureSEC source: 0001567619-21-021615 · doc1.xml · nonDerivative · entry 8 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,682 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $149.065 to $149.995. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 7,571 | $148.42 | $1,123,696.15 |
DisclosureSEC source: 0001567619-21-021615 · doc1.xml · nonDerivative · entry 7 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,531 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $148.03 to $148.995. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 13,561 | $147.65 | $2,002,304.70 |
DisclosureSEC source: 0001567619-21-021615 · doc1.xml · nonDerivative · entry 6 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,102 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $147.03 to $147.99. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,369 | $146.53 | $786,699.70 |
DisclosureSEC source: 0001567619-21-021615 · doc1.xml · nonDerivative · entry 5 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,663 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $146.095 to $146.98. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,400 | $145.66 | $786,540.78 |
DisclosureSEC source: 0001567619-21-021615 · doc1.xml · nonDerivative · entry 4 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,032 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $145.05 to $145.99. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 2,788 | $74.58 | $207,929.04 |
DisclosureSEC source: 0001567619-21-021615 · doc1.xml · nonDerivative · entry 3 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,432 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 35,232 | $11.48 | $404,463.36 |
DisclosureSEC source: 0001567619-21-021615 · doc1.xml · nonDerivative · entry 2 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,644 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 3,646 | $5.04 | $18,375.84 |
DisclosureSEC source: 0001567619-21-021615 · doc1.xml · nonDerivative · entry 1 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| November 22, 2021 Filed Nov 25, 2021 02:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 351 | $148.38 | $52,081.77 |
DisclosureSEC source: 0001567619-21-021187 · doc1.xml · nonDerivative · entry 1 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,766 F1 · shares: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 23:12 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 31,434 | $0.00 Strike: $11.48 | $0.00 |
DisclosureSEC source: 0001567619-21-019297 · doc1.xml · derivative · entry 9 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,566 Underlying: Class A Common Stock · 31,434 shares Expires 2029-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F8 · derivative.exercise_date: This option, originally for 100,000 shares, of which 31,434 shares have been exercised, vested as to 1/48th of the shares on May 1, 2019 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 23:12 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 10,232 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001567619-21-019297 · doc1.xml · derivative · entry 8 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,884 Underlying: Class A Common Stock · 10,232 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F7 · derivative.exercise_date: This option, originally for 175,000 shares, of which 124,116 shares have been exercised, vested as to 1/48th of the shares on October 1, 2018 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 23:12 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,112 | $164.75 | $512,706.36 |
DisclosureSEC source: 0001567619-21-019297 · doc1.xml · nonDerivative · entry 7 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,117 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $164.50 to $165.29. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 23:12 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 24,125 | $163.87 | $3,953,296.20 |
DisclosureSEC source: 0001567619-21-019297 · doc1.xml · nonDerivative · entry 6 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,229 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $163.48 to $164.47. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 23:12 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 11,829 | $163.15 | $1,929,949.85 |
DisclosureSEC source: 0001567619-21-019297 · doc1.xml · nonDerivative · entry 5 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,354 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $162.48 to $163.475. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 23:12 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,500 | $162.06 | $243,090.90 |
DisclosureSEC source: 0001567619-21-019297 · doc1.xml · nonDerivative · entry 4 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,183 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $161.45 to $162.43. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 23:12 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,100 | $160.50 | $176,553.96 |
DisclosureSEC source: 0001567619-21-019297 · doc1.xml · nonDerivative · entry 3 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,683 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $160.00 to $160.95. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 23:12 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 31,434 | $11.48 | $360,862.32 |
DisclosureSEC source: 0001567619-21-019297 · doc1.xml · nonDerivative · entry 2 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,783 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 23:12 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 10,232 | $5.04 | $51,569.28 |
DisclosureSEC source: 0001567619-21-019297 · doc1.xml · nonDerivative · entry 1 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,349 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 41,666 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001567619-21-017948 · doc1.xml · derivative · entry 6 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,116 Underlying: Class A Common Stock · 41,666 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F6 · derivative.exercise_date: This option, originally for 175,000 shares, of which 113,884 shares have been exercised, vested as to 1/48th of the shares on October 1, 2018 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,500 | $144.77 | $361,922.50 |
DisclosureSEC source: 0001567619-21-017948 · doc1.xml · nonDerivative · entry 5 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,117 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $144.54 to $145.02. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 21,469 | $143.97 | $3,090,891.93 |
DisclosureSEC source: 0001567619-21-017948 · doc1.xml · nonDerivative · entry 4 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,617 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $143.53 to $144.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 13,297 | $143.13 | $1,903,154.40 |
DisclosureSEC source: 0001567619-21-017948 · doc1.xml · nonDerivative · entry 3 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,086 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $142.53 to $143.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,400 | $142.16 | $625,490.80 |
DisclosureSEC source: 0001567619-21-017948 · doc1.xml · nonDerivative · entry 2 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,383 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $141.53 to $142.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 41,666 | $5.04 | $209,996.64 |
DisclosureSEC source: 0001567619-21-017948 · doc1.xml · nonDerivative · entry 1 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,783 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 23:52 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 41,666 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-21-054899 · doc4.xml · derivative · entry 8 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,782 Underlying: Class A Common Stock · 41,666 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · derivative.exercise_date: This option, originally for 175,000 shares, of which 72,218 shares have been exercised, vested as to one forty-eighth of the shares on October 1, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 23:52 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 628 | $179.20 | $112,536.03 |
DisclosureSEC source: 0001209191-21-054899 · doc4.xml · nonDerivative · entry 7 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,117 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $179.14 to $179.31. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 23:52 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 8,586 | $178.56 | $1,533,137.63 |
DisclosureSEC source: 0001209191-21-054899 · doc4.xml · nonDerivative · entry 6 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,745 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $178.14 to $179.13. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.